EUS-guided gastroenterostomy efficient in both benign, malignant diseases

The novel endoscopic ultrasound (EUS)-guided gastroenterostomy (GE) is effective in patients with either a malignant or a benign disease, reports a study. In addition, adverse events are similar in both groups.

Of the 103 patients included in the study, 72 had malignant (mean age 68 years, 57 percent female) and 31 (mean age 58 years, 39 percent female)) had benign indications.

The two groups showed comparable clinical success, technical success, average procedure time, and hospital length of stay. However, patients with a benign underlying aetiology had a significantly higher number of surgically altered midgut anatomy (p=0.0379).

“EUS-GE is equally efficient regardless of the underlying etiology (malignant vs benign), and the adverse events in both groups were comparable,” the researchers said

This study identified consecutive patients from 12 international, tertiary care centres who underwent EUS-GE over 3 years using a retrospective registry. Researchers then collected demographic characteristics, procedure-related information, and follow-up data.

The rate of adverse events associated with EUS-GE and the comparison of the rate of adverse events between benign and malignant diseases were the primary outcomes. Technical and clinical success as well as hospitalization were the secondary outcomes.

“EUS-GE is a minimally invasive therapy for patients with gastric outlet obstruction without the risks of surgical bypass and the limited long-term efficacy of enteral self-expanding metal stent placement,” the researchers said.